Senseonics (NASDAQ: SENS) closed an underwritten public offering that generated approximately $92.0 million in gross proceeds on May 4, 2026. The company sold 10,400,000 common shares (including full exercise of a 2,400,000-share underwriter option) and issued 8,000,000 pre-funded warrants.
Common shares were sold at $5.00 each and pre-funded warrants at $4.999 each. TD Cowen and Barclays acted as joint book-running managers; Mizuho and Lake Street were bookrunners. The offering was made under a Form S-3 shelf registration effective August 18, 2025.
Loading...
Loading translation...
Positive
Gross proceeds of approximately $92.0 million raised
10,400,000 common shares sold including full 2,400,000 underwriter option exercise
Issued 8,000,000 pre-funded warrants to certain investors
Public offering priced at $5.00 per common share
Negative
Issuance of common shares and 8,000,000 pre-funded warrants may dilute existing shareholders
News Market Reaction – SENS
-0.20%
-0.20%Session close to close
In the May 5 session, SENS declined 0.20%, reflecting a mild negative market reaction.
This announcement details the closing of a $92.0 million underwritten public offering of common stoc...
Analysis
This announcement details the closing of a $92.0 million underwritten public offering of common stock and pre-funded warrants at $5.00 per share. It fits within a broader capital-raising framework that includes a $300 million Form S-3 shelf and prior offerings, alongside recent growth initiatives for the Eversense 365 platform. Investors may watch how proceeds are allocated toward commercialization, pipeline development, and balance-sheet objectives in upcoming updates.
Key Figures
Public offering size:$92.0 millionCommon shares sold:10,400,000 sharesPre-funded warrants:8,000,000 warrants+5 more
8 metrics
Public offering size$92.0 millionGross proceeds before underwriting discounts and expenses
Common shares sold10,400,000 sharesIncludes 2,400,000 shares from underwriters’ option
Pre-funded warrants8,000,000 warrantsIssued in lieu of common stock to certain investors
Common stock price$5.00 per sharePublic offering price for common shares
Pre-funded warrant price$4.999 per warrantEquals share price minus $0.001 exercise price
Warrant exercise price$0.001 per shareExercise price for each pre-funded warrant
Shelf capacity$300 millionMaximum aggregate amount under Form S-3 universal shelf
ATM program size$100 millionAt-the-market offering capacity with TD Cowen
Announced $16M registered direct stock and warrant offering for funding needs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Past capital-raising news led to a modest share-price decline, and the current offering also coincides with a sharp negative move.
Recent Company History
Recent news centered on product approvals and launches for Eversense 365, integration with automated insulin delivery systems, and strong revenue growth in 2025. Those operational updates produced mixed but generally modest price reactions, including both gains and declines under 6%. In contrast, the capital-raising history shows a prior $16 million registered direct offering in October 2024 that triggered a -2.99% move. Today’s larger underwritten public offering fits into that ongoing funding pattern.
Key Terms
pre-funded warrants, shelf registration statement, form s-3, prospectus supplement, +2 more
6 terms
pre-funded warrantsfinancial
"and, in lieu of common stock to certain investors, pre-funded warrants."
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shelf registration statementregulatory
"The offering was made pursuant to a “shelf” registration statement on Form S-3,"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
form s-3regulatory
"registration statement on Form S-3, including a base prospectus (File No. 333-289306)"
Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.
prospectus supplementregulatory
"A prospectus supplement and accompanying prospectus relating to the proposed offering"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
securities and exchange commissionregulatory
"filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2025"
A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.
underwritten public offeringfinancial
"closing of its previously announced underwritten public offering of $92 million of shares"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Senseonics sold 10,400,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 2,400,000 additional shares of common stock, and 8,000,000 pre-funded warrants. The shares of common stock were sold at a price to the public of $5.00 per share and the pre-funded warrants were sold at a purchase price of $4.999 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Senseonics from the offering were approximately $92.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Senseonics.
TD Cowen and Barclays acted as joint book-running managers and Mizuho and Lake Street acted as bookrunners for the offering.
The offering was made pursuant to a “shelf” registration statement on Form S-3, including a base prospectus (File No. 333-289306) that was originally filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2025 and became effective on August 18, 2025. A prospectus supplement and accompanying prospectus relating to the proposed offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, by contacting TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
INVESTOR CONTACT: Jeremy Feffer LifeSci Advisors investors@senseonics.com
FAQ
What did Senseonics (SENS) announce on May 4, 2026 about its financing?
Senseonics closed an underwritten public offering raising approximately $92.0 million. According to the company, the offering included 10,400,000 common shares and 8,000,000 pre-funded warrants.
How many shares did Senseonics sell and what was the offering price per share (SENS)?
Senseonics sold 10,400,000 common shares at $5.00 per share. According to the company, pre-funded warrants were sold at $4.999 each, reflecting a $0.001 exercise price.
Did Senseonics (SENS) exercise the underwriters' option in the offering?
Yes. According to the company, the public offering included the full exercise of the underwriters’ option to purchase 2,400,000 additional common shares.
Who managed the Senseonics (SENS) May 4, 2026 offering and under what registration?
TD Cowen and Barclays acted as joint book-running managers; Mizuho and Lake Street were bookrunners. According to the company, the offering used a Form S-3 shelf registration effective August 18, 2025.
What is the shareholder impact of the Senseonics (SENS) offering?
The offering increased outstanding equity via 10,400,000 shares and 8,000,000 pre-funded warrants, which may dilute existing holders. According to the company, gross proceeds were ~$92.0 million.
